TFC Therapeutics is developing a monoclonal antibody technology that specifically targets and eliminates TMH cells, which are key drivers of cancer recurrence and metastasis. This approach activates the immune system to destroy these resilient cancer cells, offering a new treatment option for preventing cancer relapse.
Funding
$13.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer recurrence and metastasis are often driven by tumor-initiating or metastasis-initiating cells (TMH cells) that are resistant to conventional therapies. These cells can survive initial treatment and lead to relapse or spread of the disease.
Solution
TFC Therapeutics is developing a monoclonal antibody technology designed to selectively target and eliminate TMH cells. By specifically binding to these cells, the antibody aims to trigger an immune response that destroys them, preventing cancer recurrence and metastasis. This approach offers a novel therapeutic strategy to address the root cause of relapse by eradicating the resilient cancer cells responsible for disease progression. The technology seeks to provide a more effective and durable treatment option for patients at risk of cancer recurrence.
Target Audience
The primary target audience includes cancer patients at high risk of recurrence and healthcare providers seeking novel therapeutic options to prevent relapse and metastasis.
Features
- Monoclonal antibody technology specifically targeting TMH cells
- Mechanism of action involves activating the immune system to eliminate targeted cells
- Designed to prevent cancer recurrence and metastasis